Boston Scientific's ACURATE Neo2 Aortic Valve System Fails To Meet Non-Inferiority In Key Trial, Showing 16.16% Composite Rate Of Mortality, Stroke, Or Rehospitalization At One Year Versus 9.53% For Control Valve; Data Presented At TCT 2024
Boston Scientific's ACURATE Neo2 Aortic Valve System Fails To Meet Non-Inferiority In Key Trial, Showing 16.16% Composite Rate Of Mortality, Stroke, Or Rehospitalization At One Year Versus 9.53% For Control Valve; Data Presented At TCT 2024
波士顿科学的ACURATE Neo2主动脉瓣系统在关键试验中未达到非劣效性，一年内死亡、中风或再入院的综合发病率为16.16%，而对照组瓣膜为9.53%；数据在TCt 2024年展示。
Boston Scientific's ACURATE Neo2 Aortic Valve System Fails To Meet Non-Inferiority In Key Trial, Showing 16.16% Composite Rate Of Mortality, Stroke, Or Rehospitalization At One Year Versus 9.53% For Control Valve; Data Presented At TCT 2024
波士顿科学的ACURATE Neo2主动脉瓣系统在关键试验中未达到非劣效性，一年内死亡、中风或再入院的综合发病率为16.16%，而对照组瓣膜为9.53%；数据在TCt 2024年展示。
资讯热榜
更新时间